A 2018 study in PNAS that claimed to show a biotech company’s platform for creating immunotherapies was better than existing methods has earned an expression of concern over the reproducibility of some of its findings.
When the article appeared, STAT called “Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo,” a “major paper that showed more clearly why companies like Roche are so interested in using its technique.”
The technique was developed by SQZ Biotech, which was founded by MIT’s Robert Langer, a founder or co-founder of numerous biotechs including Moderna, and with whom Roche partnered in 2015.
The paper has been cited 55 times, according to Clarivate Analytics’ Web of Science. According to a press release announcing the work:
Continue reading Biotech’s ‘cell squeezing’ technology paper earns expression of concern